Brought to you by 
Novo Nordisk, Schering end Prandin co-promotion
03 Apr 2000
Executive Summary
Novo Nordisk and Schering-Plough agreed to jointly launch and promote Novo's Prandin (repaglinide), an oral antidiabetic agent for the treatment of Type II diabetes, and Novo Nordisk's full range of insulin products and devices, in the US.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo Nordisk, Schering end Prandin co-promotion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice